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Yale school of Medicine produced the first proof-of-concept study on the viability of a “morn-
ing-after” pill for human use. This study was a result of a fruitful collaboration between a
pair of Yale scientists, Drs. John M. Morris and Gertrude van Wagenen, who sought a non-
abortion, post-coital contraceptive. They tested a variety of hormones, hormone-based syn-
thetic drugs, and other compounds in monkeys in an effort to uncover a compound that was
non-toxic but highly effective. Unfortunately, although they were unable to identify such a
drug, their initial studies inspired other scientists to further pursue the concept of a “morn-
ing-after” pill, leading to the development of Food and Drug Administration (FDA†)-approved
emergency contraceptives.
In 1966, two Yale School of Medicine
researchers published a small study that
showed for the first time that certain estro-
genic compounds can prevent pregnancy if
taken within a few days after sexual inter-
course [1,2]. This was the first instance of
a compound successfully used as a “morn-
ing-after” pill. The authors of this study,
John McLean Morris, MD, and Gertrude
van Wagenen, PhD, both members of the
Department of Obstetrics and Gynecology,
undertook a collaboration that generated
six  peer-reviewed  publications  that  ex-
plored the use of various compounds as
emergency contraception. Dr. van Wage-
nen’s expertise in using rhesus macaque
monkeys, Macaca mulatta, as a model sys-
tem and Dr. Morris’ interest in developing
new contraceptive methods set the stage for
these pioneering studies. Yale School of
Medicine was an ideal place for these types
of investigations because it housed a suc-
cessful breeding population of macaque
monkeys and possessed well-documented
records on their fertility over a long period.
When these studies were undertaken, it
was already known that estrogenic com-
pounds at a sufficient dosage prevent ovum
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stilbestrol; ethinyl estradiolimplantation  in  some  non-primate  mam-
malian animals, such as rabbits [1]. It was
also well-known that an optimum balance of
estrogen and progesterone is needed to pro-
mote implantation, implying that changing
the ratios of different hormones can influ-
ence  the  probability  of  implantation  [3].
However, the estrogenic compounds used in
these early studies were not examined for
toxicity in humans, making these drugs un-
usable in a clinical setting. Morris and van
Wagenen made use of the fact that the repro-
ductive system in Macaca mulatta is very
similar to that of humans. More specifically,
female rhesus macaque monkeys are known
to have a comparable menstrual cycle, de-
pendent on changes in hormonal levels, to
human females, making them an ideal model
system to test estrogenic candidates.
In their first study, Morris and van Wa-
genen tested several known estrogens and a
novel compound, ORF-3858, developed by
the Ortho Research Foundation in New Jer-
sey. This new compound was previously
shown to be 100 percent effective in pre-
venting ovum implantation in rabbits. An-
other distinction was that this compound
was non-toxic and non-teratogenic, meaning
that it did not impair the growth of an al-
ready implanted embryo, even when given
at doses that did not prevent implantation. In
monkeys, this compound also proved to be a
100 percent effective when given orally for
6 days after mating.  
Since further characterization of ORF-
3858 showed that this molecule had estro-
genic properties, established estrogens were
re-evaluated  for  their  anti-implantation
properties. Morris and van Wagenen had
shown that diethylstilbestrol, ethinyl estra-
diol, and mestranol prevented implantation
in rabbits very efficiently [1]. These same
compounds were ineffective in preventing
implantation in monkeys at the same dosage,
but when the concentration was increased
and treatment given orally or by intramus-
cular injection for 6 days, they were able to
prevent  ovum  implantation.  This  set  the
stage for a preliminary clinical trial that
showed that 50 mg of diethylstilbestrol or
0.5 mg of ethinyl estradiol for 4 to 6 days
after coitus was effective in preventing preg-
nancy. Though this study was not statisti-
cally significant, it represented the first time
that prevention of implantation was demon-
strated in humans [2].  
Unfortunately,  diethylstilbestrol  and
ethinyl estradiol have several side effects,
such as nausea and breast soreness, which
are common to estrogenic compounds. An
ideal  post-coital  contraceptive  would  be
non-toxic, non-teratogenic, highly effective
against implantation of the ovum, and ex-
hibit few side effects. In an effort to find
such compounds, Morris and van Wagenen
turned to alkaloids and antimetabolites to
possibly identify a drug that would be effec-
tive yet induce few negative effects. They
tested several compounds previously indi-
cated to have an effect in rodents, rabbits,
and monkeys. They found that some mole-
cules such as colcemide were very effective
in preventing a full-term pregnancy but did
so by being extremely toxic to the develop-
ing fetus, not by preventing implantation.
This drug also proved to be extremely toxic,
particularly because the effective dosage
was  very  close  to  the  toxic  dosage  [3].
Moreover, colcemide was ineffective at pre-
venting pregnancy in primates. They found
that these compounds did not produce the
same effect in rabbits and primates and the
method of delivery (oral or intra-peritoneal
injection) of the drug seemed to change its
efficacy [3].
In light of these issues with non-estro-
genic compounds, the Morris and van Wa-
genen team turned back to examining the
use of synthetic estrogens and antiestrogens
to prevent the implantation of the ovum.
Synthetic estrogens were especially of in-
terest because they had been shown to act as
competitive  inhibitors  of  estrogen  while
being poorly estrogenic themselves. When
several such compounds were tested in rab-
bits  and  monkeys,  a  few,  such  as
clomiphene, showed low effectiveness and
produced severe side effects, such as pro-
longed amenorrhea [4]. ORF-3858 was the
only compound that showed high effective-
ness in preventing pregnancy in monkeys at
a dose of 2 mg/kg for 6 days after mating
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cycle [4].
This novel compound showed promise
in being used as an anti-implantation drug,
but its mechanism of action was still un-
known. To study this more extensively, the
uterine tissue of both untreated and treated
animals was examined. With ORF-3858,
the endometrium seemed to undergo de-
generation, but the fetus and fetal mem-
branes  were  intact  [4].  Treatment  with
other  compounds,  such  as  clomiphene,
seemed to directly affect the blastocyst. To
test if the effect was exerted on the en-
dometrium or on the blastocyst, Morris and
van Wagenen performed a blastocyst trans-
fer experiment by extracting blastocysts
from either a treated or untreated uterus,
transferring it to another uterus, and meas-
uring the rate at which implantation oc-
curred. There was no significant difference
between the implantation of blastocysts in
the control and treatment groups, showing
that the blastocyst itself was unaffected by
drug treatment [4].
To better understand what effect these
estrogenic compounds were having, Morris,
van Wagenen, and colleagues took blood
samples from untreated and treated post-
ovulation monkeys and analyzed these sam-
ples’ prostaglandin and progesterone levels.
Progesterone levels dropped rapidly after
treatment, while prostaglandin levels rose at
the same time [5]. Unfortunately, this was
not enough to establish a causal relationship
between the changes in these hormones and
the anti-implantation properties exhibited by
the estrogenic compounds tested.  
Morris and van Wagenen were in search
of a molecule that prevented implantation,
for which they adopted the term “intercep-
tives” [6]. These were different from aborti-
facients, since implantation would not have
occurred. In 1977, Yupze and Lance devel-
oped an emergency contraception regimen
for humans of 0.1 mg ethinylestradiol and
0.5 mg levonorgestrel [7], and this combi-
nation regimen was in place as a emergency
contraception method until it was replaced
recently with a levonorgestrel-alone treat-
ment marketed as Plan B [8]. Though the
mechanism of action of levonorgestrel is
still unknown, it has been shown to not to be
an “interceptive” [8]. Thus, although Morris
and van Wagenen’s goal was not achieved,
their initial studies of the effects of estro-
genic compounds on ovum implantation in
monkeys, based on the idea that disturbing
hormonal balance can prevent implantation,
paved the way for the discovery of the post-
coital emergency contraceptives approved
by the FDA for human use today.
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